Skip Navigation Links
Multicenter Phase II Study of Transanal TME (taTME)
Overall Recruitment Status: Active, currently enrolling
 
Official Title
Multicenter Phase II Study of Transanal Total Mesorectal Excision (taTME) With Laparoscopic Assistance for Rectal Cancer
 
Region Sponsors
California - Southern
Icahn School of Medicine at Mount Sinai
 
Acronym KP IRB No.
(taTME) 11395
 
Study Type Phase
Clinical Trial Phase II
 
Study Population Description
(Adult, Older Adult) with new diagnosis of histologically confirmed Rectal Cancer, Surgery
 
Purpose
Radical rectal cancer resection, namely total mesorectal excision (TME), is the cornerstone of the treatment of resectable rectal cancer. In combination with chemotherapy and radiation treatment (CRT), complete TME with negative resection margins is associated with sustained local and systemic control even in locally advanced disease. Over the last 2 decades, laparoscopic and robotic techniques have been increasingly adopted due to reduced surgical trauma and faster patient recovery. Yet, both approaches are associated with equivalent postoperative morbidity and disturbances in sexual, urinary and defecatory function relative to open TME. Furthermore, laparoscopic and robotic TME remain associated with substantial conversion rates and variable rates of TME completeness as a result of the procedural difficulties reaching the low rectum from the abdominal approach. Transanal TME (taTME) with laparoscopic assistance was developed to facilitate completion of TME using a primary transanal endoscopic approach. Transanal TME uses a "bottom-up approach" to overcome the technical difficulties of low pelvic dissection using an abdominal approach. Published results from single-center taTME series and an international registry suggest the short-term procedural and oncologic safety of this approach in resectable rectal cancer. No multicenter phase II study has yet been conducted to validate the procedural safety, functional outcomes or long-term oncologic outcomes of this approach. Study Design: This is a 5-year phase II multicenter single-arm study to evaluate the safety and efficacy of low anterior resection (LAR) with taTME using laparoscopic or robotic assistance in 100 eligible subjects with resectable rectal cancer. Hypothesis: taTME is non-inferior to standard LAR with respect to the quality of the TME achieved.
 
Detailed Description
This study is the first phase II multicenter trial of taTME conducted in the United States to evaluate the efficacy and safety of taTME with laparoscopic or robotic assistance relative to standard LAR. A total of 100 subjects with resectable rectal cancer located up to 10 cm from the anal verge will be enrolled across 10 US study sites. It is anticipated that this larger, phase II multicenter study will validate the safety and efficacy of taTME with respect to perioperative outcomes, short and long-term oncologic outcomes and functional results. Study procedures will consist in 1-team (sequential) or 2-team (combined) LAR with transanal TME using laparoscopic or robotic abdominal assistance. Laparoscopic or robotic abdominal access will be obtained followed by inferior mesenteric vessels transection, mobilization or the proximal colon and splenic flexure takedown if indicated. Transanal TME is performed either at the same time or following the above steps. Intersphincteric resection (ISR) may be included for very low tumors. Following pursestring closure of the rectum below the tumor, transanal endoscopic TME dissection will proceed circumferentially until the peritoneal cavity is entered anteriorly. Following complete mobilization of the rectosigmoid, the specimen is extracted transanally or transabdominally followed by colorectal or coloanal anastomosis, with or without a diverting loop ileostomy. Operative details will be recorded in case report forms (CRF's).
 
Gender Age Limit
Male & Female 18 years & older
 
Inclusion Criteria
  • New diagnosis of histologically confirmed adenocarcinoma of the rectum
  • Age = >18
  • Clinical stage cT1 (high-risk), T2, or T3, cN0, N1, N2 on staging pelvic MRI
  • Negative predicted CRM on staging pelvic MRI
  • No evidence of metastasis on CT scans of the chest, abdomen and pelvis
  • Rectal cancer located within 10 cm from the anal verge based on proctoscopy and digital rectal examination (DRE)
  • Complete preoperative colonoscopy demonstrating no synchronous colon cancer
  • Eastern Cooperative Oncology Group (ECOG) performance status <2 (Karnofsky = >60%)
  • Eligible to undergo laparoscopic or robotic LAR with or without a temporary diverting stoma, based on multidisciplinary tumor board consensus
  • Able to understand and willing to sign a written informed consent form
 
Exclusion Criteria
  • cT4 on staging pelvic MRI
  • >12 weeks delay between completion of neoadjuvant CRT and planned study procedure
  • Severely symptomatic rectal tumors
  • Tumors invading into the internal anal sphincter muscle based on DRE and pelvic MRI
  • Fecal incontinence at baseline
  • Prior history of rectal resection
  • Prior history of colorectal cancer
  • History of inflammatory bowel disease
  • Uncontrolled concurrent illness
  • Pregnancy
  • Subjects who cannot read or understand English

 
Keywords and/or Specific Medical Conditions
  • Digestive System Diseases
  • Neoplasms by Site
  • Digestive System Neoplasms
  • Rectal Cancer
  • Gastroenterology
  • Rectal Diseases
  • Gastrointestinal Diseases
  • Rectal Neoplasms Colorectal Neoplasms
  • Gastrointestinal Neoplasms
  • Surgery
  • Intestinal Diseases
  • Surgery (Colon and Rectal)
  • Intestinal Neoplasms
  • Oncology (Adult)
  • Neoplasms
 
KP Clinical Facility
  • Los Angeles (Sunset)
 
Clinical Area
  • Gastroenterology
  • Oncology (Adult)
  • Surgery (Colon and Rectal)


Principal Investigator:
Elisabeth McLemore, MD
Contact Information:
- Cynthia Brown
-(626) 564-7845
-clinical.trials@kp.org
-Los Angeles (Sunset)


smilelady1
Do you want to receive
Email Alerts?

Sign Up Here!





Regional Research Sites: